Prostate Cell News Volume 6.27 | Jul 24 2015

Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Anti-Tumor Effect of Docetaxel in Prostate Cancer
The effect of PF-03084014 on response to docetaxel was evaluated in docetaxel-sensitive and -resistant castration-resistant prostate cancer cell lines in vitro and in murine models. Impacts on cell proliferation, apoptosis, cancer stem cells and angiogenesis were evaluated. [Clin Cancer Res] Abstract

The Use of Collagen-Based Scaffolds to Simulate Prostate Cancer Bone Metastases with Potential for Evaluating Delivery of Nanoparticulate Gene Therapeutics
Scientists established a 3D cell culture model of prostate cancer bone metastasis using collagen-based scaffolds, characterized this model, and assessed the potential of the model to evaluate delivery of gene therapeutics designed to target bone metastases. [Biomaterials] Abstract

Hypoxia-Inducible miR-182 Enhances HIF1α Signaling via Targeting PHD2 and FIH1 in Prostate Cancer
Overexpression of miR-182 in prostate cancer cells led to a reduction of prolyl hydroxylase domain enzyme 2 (PHD2) and factor inhibiting hypoxia-inducible factor 1 (HIF-1) (FIH1) expression and an increase in HIF1α level either under normoxic or hypoxic condition. [Sci Rep] Full Article

TRAIL-Troglitazone-Induced Apoptosis in Prostate Cancer Cells Involve AMP-Activated Protein Kinase
Since troglitazone is known to activate AMP-activated protein kinase (AMPK), the authors determined whether AMPK is a molecular target mediating this apoptotic cascade by utilizing prostate cancer cell lines stably overexpressing AMPKα1-dominant negative or empty vector. [J Biol Chem] Abstract | Full Article

Delivery of Retinoic Acid to LNCap Human Prostate Cancer Cells Using Solid Lipid Nanoparticles
Anticancer efficiency was evaluated by incubating retinoic acid-solid lipid nanoparticles (SLNs) with human prostate cancer (LNCap) cells, which demonstrated reduced cell viability with increased drug concentrations while blank SLNs displayed negligible cytotoxicity. [Int J Pharm] Abstract

Pituitary Tumor-Transforming Gene 1 Regulates Invasion of Prostate Cancer Cells through MMP13
In vitro, pituitary tumor-transforming gene 1 (Pttg1) activated matrix metalloproteinase 13 (MMP13), which determined prostate cancer (PC) cell invasiveness. However, Pttg1 levels were not significantly affected by MMP13. Furthermore, the Pttg1-activated MMP13 in PC cells was significantly suppressed by inhibition of PI3k/Akt, but not ERK/MAPK or JNK pathways. [Tumour Biol] Abstract

Targeted Nanomedicine for Prostate Cancer Therapy: Docetaxel and Curcumin Co-Encapsulated Lipid–Polymer Hybrid Nanoparticles for the Enhanced Anti-Tumor Activity In Vitro and In Vivo
Docetaxel and curcumin co-encapsulated lipid–polymer hybrid nanoparticles (LPNs) were constructed. The cytotoxicity of the LPNs was evaluated on PC-3 human prostate carcinoma cells by MTT assays. [Drug Deliv] Abstract

The GnRH Antagonist Degarelix Directly Inhibits Benign Prostate Hyperplasia Cell Growth
Benign prostate hyperplasia (BPH)-isolated epithelial and stromal cells were either cultured alone or co-cultured and subsequently treated with increasing concentrations of degarelix. Degarelix treatment induced a decrease in cell viability and cell proliferation rates, which occurred in parallel to an increase in apoptosis. [Horm Metab Res] Abstract

CLINICAL RESEARCH

Novel Biomarker Signature that May Predict Aggressive Disease in African American Men with Prostate Cancer
Scientists studied the ethnicity-specific expression of prostate cancer (PC)–associated biomarkers to evaluate whether genetic/biologic factors affect ethnic disparities in PC pathogenesis and disease progression. [J Clin Oncol] Abstract | Press Release

Efficacy of Cabazitaxel in Castration-Resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells
The authors investigated the association between androgen receptor splice variant 7 (AR-V7) expression in circulating tumor cells and resistance to cabazitaxel. They selected patients with metastatic castration-resistant prostate cancer (mCRPC) from the multicenter, randomized, Phase II, open-label study in mCRPC on the pharmacodynamic effects of budesonide on cabazitaxel. [Eur Urol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

From our sponsor: Learn how to form and isolate neural rosettes more efficiently. Watch the video.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

Research Assistant/Associate – Computational Biologist (University of Glasgow)

Postdoctoral Positions – Cancer Research (Rutgers University)

Postdoctoral Position – Functional Cancer Genomics (Institute of Oncology Research)

Assistant Professor- Urology (University of California, Los Angeles)

Postdoctoral Fellow- Oncology (Oregon Health & Science University)

Postdoctoral Fellows – Molecular Mechanisms of Prostate Cancer Progression and Therapeutic Resistance (Tulane University School of Medicine)

Postdoctoral Fellowship – Molecular Mechanisms and Translational Investigations of Advanced Prostate Cancer (Cleveland Clinic Lerner Research Institute)

Research Scientists – Tissue Biorepository and Data Resource for Prostate Cancer (NYU Langone Medical Center)

Postdoctoral Technician – Prostate/Breast Cancer (Baylor College of Medicine)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.